Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience

Martina Budel, Luca Martella, Laura Zambon, Isabella Morson, Giorgio Giorda, Renato Cannizzaro

Research output: Contribution to journalComment/debatepeer-review

Abstract

The Commentary reports on our experience in Centro di Riferimento Oncologico IRCCS Aviano about the integrated and combined treatment with percutaneous endoscopic gastrostomy and lanreotide in patients with bowel obstructions by ovarian cancer and peritoneal carcinomatosis. We treated patients with gynecological cancers and bowel obstruction with percutaneous endoscopic gastrostomy and, when patients were partially responsive, with lanreotide. We registered a constant overall benefit for the quality of life and for the control of symptoms, which is very important especially during the home care follow-up of terminal patients.

Original languageEnglish
Pages (from-to)547-549
Number of pages3
JournalSupportive Care in Cancer
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 2021

Keywords

  • Gynecological cancers
  • Lanreotide
  • Percutaneous endoscopic gastrostomy

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Intestinal occlusion by gynecological cancers treated by percutaneous endoscopic gastrostomy and lanreotide: an Aviano National Cancer Institute experience'. Together they form a unique fingerprint.

Cite this